Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).

Ian Benjamin Gaddie,Eric D Donnenfeld,Paul Karpecki,Patrick Vollmer,Gregg J Berdy, Jared D Peterson,Blake Simmons, Aimée R P Edell, William E Whitson,Joseph B Ciolino,Stephanie N Baba,Mark Holdbrook, José Trevejo,John Meyer,Elizabeth Yeu

Ophthalmology（2023）

引用 0|浏览0

暂无评分

摘要

Twice-daily treatment with lotilaner ophthalmic solution, 0.25% for 6 weeks was generally safe and well tolerated and met the primary endpoint and all secondary endpoints for the treatment of Demodex blepharitis compared to the vehicle control.

查看译文

关键词

Blepharitis,Demodex blepharitis,Lotilaner ophthalmic solution 0.25%,Lotilaner phase 3 clinical trial,Treatment of Demodex blepharitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要